Payment is a benefit and why it matters for pediatric trials
Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. F...
Main Author: | |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
Wiley-Blackwell
2022
|
In: |
Bioethics
Year: 2022, Volume: 36, Issue: 7, Pages: 757-764 |
IxTheo Classification: | NCH Medical ethics NCJ Ethics of science |
Further subjects: | B
benefit analyses / risk
B research ethics B children and families |
Online Access: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
Summary: | Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. First, I explain why the practical implications of these arguments for studies enrolling competent adults are less than fully clear. Second, I explain why the practical implication for trials enrolling children are clear and significant. I argue that we should be comfortable paying children to compensate them for undergoing research risks. I propose we do so by putting money into accounts that the child gains access to upon attaining majority. |
---|---|
ISSN: | 1467-8519 |
Contains: | Enthalten in: Bioethics
|
Persistent identifiers: | DOI: 10.1111/bioe.13011 |